Results 211 to 220 of about 259,118 (384)

Captopril, a Renin–Angiotensin System Inhibitor, Attenuates Tumour Progression in the Regenerating Liver Following Partial Hepatectomy [PDF]

open access: gold, 2022
Georgina Riddiough   +9 more
openalex   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

The modeling and simulation of feedback control systems [PDF]

open access: yes
A brief description of the principles of mathematical models and their development is given.
Leonard, J. I.
core   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino   +14 more
wiley   +1 more source

Renin‐angiotensin System Activation in Congenital Hepatic Fibrosis in the PCK Rat Model of Autosomal Recessive Polycystic Kidney Disease

open access: green, 2010
Miwa Goto   +5 more
openalex   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki   +3 more
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami   +16 more
wiley   +1 more source

Repurposing Renin-Angiotensin System Drugs for the Treatment of Audiovestibular Disorders. [PDF]

open access: yesJ Clin Med
Podhajsky G   +7 more
europepmc   +1 more source

Effect of preoperative SGLT2 inhibitor use on postoperative acute kidney injury in patients with type 2 diabetes undergoing surgery: A causal inference study using routinely collected data

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess whether preoperative sodium‐glucose co‐transporter 2 inhibitor (SGLT2i) use reduces the odds of postoperative acute kidney injury (AKI) in patients with type 2 diabetes undergoing surgery. Methods We conducted a target trial emulation using inverse probability of treatment weighting, utilising routinely collected data from a ...
Frank M. Gao   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy